title: [Clinical effects of increase in the loading dose of tamsulosin (from 0.2 mg to 0.3 mg) on urinary disturbance associated with benign prostate hyperplasia].
abstract: We determined the clinical efficacy of a loading dose of tamsulosin (0.2-0.3 mg) in patients with benign prostate hyperplasia (BPH). Tamsulosin was administered at a dose of 0.3 mg to 26 patients with BPH and moderate or severe urinary disturbance, as determined on the basis of the international prostate symptom score (I-PSS) and quality of life (QOL) severity. The I-PSS and QOL index were calculated before and at the end of the 12-week administration period. The total I-PSS and QOL index were significantly decreased at 12 weeks compared with the baseline (p=0.003, and p=0.011, respectively). Significant differences were observed in the changes in 3 I-PSS items (stream, p=0.042 ; nocturia, p=0.012 ; urgency, p=0.003). On the basis of these findings, we conclude that the administration of 0.3 mg tamsulosin to patients with BPH improves the scores of objective indexes, and may specifically ameliorate urinary storage symptoms.
authors.affiliation: The Department of Urology, Kouseikai Hospital.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Hisamatsu
authors.forename: Syuji
authors.initials: S
authors.lastname: Yamashita
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage*; D000368:Aged; D006801:Humans; D008297:Male; D017060:Patient Satisfaction; D011470:Prostatic Hyperplasia / Q000150:complications*; D011788:Quality of Life; D013449:Sulfonamides / Q000008:administration & dosage*; D000077409:Tamsulosin; D014555:Urination Disorders / Q000188:drug therapy* / Q000209:etiology
chemical_list: D000317:Adrenergic alpha-Antagonists; D013449:Sulfonamides; D000077409:Tamsulosin